Clinical Trials for Ovarian Cancer

A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Enrolling adults with platinum-resistant, high-grade serous epithelial ovarian/primary peritoneal/fallopian tube cancer with high FRα expression (Ventana FOLR1 ≥75% 2+), ECOG 0–1, measurable disease. Investigates mirvetuximab soravtansine, an FRα-targeted antibody–drug conjugate delivering the microtubule inhibitor DM4, comparing Q3W standard dosing vs a split-dose Q4W schedule; includes a separate cohort to define starting dose in moderate hepatic impairment.

ClinicalTrials.gov ID: NCT06682988

Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Enrolling adults with platinum-refractory or -resistant ovarian, fallopian tube, or primary peritoneal carcinoma (any prior lines; prior anti-VEGF allowed; ECOG 0–1) to receive weekly paclitaxel plus bevacizumab with added lurbinectedin. Lurbinectedin is a DNA minor-groove binding transcription inhibitor (RNA Pol II degradation) with myelosuppression risk; study defines a safe dose and assesses preliminary activity.

ClinicalTrials.gov ID: NCT05636111

Phase 1 Clinical Trial Using Autologous, MUC1-Activated T Cells Expanded from Peripheral Blood in Patients with Relapsed and Resistant Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Single-arm dose-escalation evaluating autologous, ex vivo–expanded MUC1-activated T cells after lymphodepleting chemotherapy in adults with relapsed/refractory MUC1-positive epithelial ovarian, fallopian tube, primary peritoneal carcinoma, or carcinosarcoma (ECOG 0–1; prior platinum; PARP inhibitor required for BRCA1/2-mutated). Investigational therapy is adoptive transfer of MUC1-reactive T cells (targeting the tumor-associated mucin MUC1) with optional second infusion on day 21; key exclusions include active CNS disease, prior MUC1 therapy, significant cardiac disease, uncontrolled autoimmune/infectious conditions, and chronic high-dose steroids.

ClinicalTrials.gov ID: NCT06483048

A Phase 1a/1b Study of 27T51, an Anti-MUC16 CAR T Cell Drug Product Administered Alone or in Combination for Participants With Recurrent or Refractory Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ECOG 0–1, measurable disease, elevated CA-125) receive 27T51, an autologous anti-MUC16 CAR T-cell therapy, as monotherapy or combined with the PD-1 inhibitor cemiplimab with or without bevacizumab. Excludes significant organ dysfunction, low ALC at leukapheresis, active CNS pathology, recent significant autoimmune disease on immunosuppression, and prior cellular/gene therapy.

ClinicalTrials.gov ID: NCT06469281

Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Adults with stage IIIC–IV high-grade epithelial ovarian, primary peritoneal, or fallopian tube carcinoma who respond to 3–4 cycles of platinum-based neoadjuvant chemotherapy and are candidates for interval debulking are randomized to minimally invasive cytoreduction (with possible conversion) versus open laparotomy, followed by standard adjuvant chemotherapy. No investigational drugs; the trial tests surgical approach impact on disease-free survival, cytoreduction rates, QoL, and perioperative outcomes.

ClinicalTrials.gov ID: NCT04575935

The Efficacy of T-regulatory Cell Depletion with E7777 Combined with Immune Checkpoint Inhibitor, Pembrolizumab, in Recurrent or Metastatic Solid Tumors: Phase I/II Study

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent/metastatic solid tumors that progressed on standard therapy (Phase I: pembrolizumab-appropriate tumors; expansion: platinum-resistant ovarian cancer without prior PD-1/PD-L1 and MSI-H cancers post–PD-1/PD-L1) receive pembrolizumab plus E7777 (denileukin diftitox), a CD25-directed IL-2–diphtheria toxin fusion that depletes T-regulatory cells. E7777 is given days 1–3 of 21-day cycles (dose-escalation to RP2D, up to 8 cycles) with fixed-dose pembrolizumab, continuing until progression/toxicity.

ClinicalTrials.gov ID: NCT05200559

A Phase II Study in Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer Evaluating Carbo/Taxol/Pembro in Patients Receiving Neoadjuvant Chemotherapy (NACT) Followed by Olaparib/Pembro Maintenance

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Single-arm study for adult women (ECOG 0–1) with newly diagnosed FIGO stage III/IV epithelial ovarian, primary peritoneal, or fallopian tube cancer planned for neoadjuvant carboplatin/paclitaxel and interval debulking surgery. Treatment: lead-in carbo±taxol, then carbo/taxol plus pembrolizumab (anti–PD-1) pre- and post-surgery, followed by maintenance olaparib (PARP inhibitor) plus pembrolizumab; bevacizumab allowed post-op and into maintenance as indicated.

ClinicalTrials.gov ID: NCT05952453

A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Recurrent Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent platinum-resistant or intolerant high-grade serous or endometrioid ovarian cancer confined to the abdomen/pelvis receive intraperitoneal autologous cytokine-induced memory-like (CIML) NK cells after lymphodepletion, supported by low-dose IL-2. CIML NK cells are ex vivo cytokine-preactivated NK cells designed to enhance cytotoxicity and persistence; prior PARP inhibitor is required for BRCA1/2-mutant patients, and prior checkpoint inhibitor is allowed if tolerated.

ClinicalTrials.gov ID: NCT06321484

Combination of the Hypomethylating Agent Decitabine and the Nuclear Export Receptor XPO-1 Inhibitor Selinexor to Reverse Platinum Resistance in Relapsed/Refractory Epithelial Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with relapsed/refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma after prior platinum/taxane therapy receive carboplatin/paclitaxel plus decitabine, with selinexor (XPO1 inhibitor) added from cycle 2, aiming to overcome platinum resistance. Includes patients with ECOG 0–2 and stable treated CNS mets; excludes prior XPO1 inhibitor exposure or intolerance to platinum/taxane.

ClinicalTrials.gov ID: NCT05983276

Study of NMS-03305293, a Non-Trapping PARP1-Specific PARP Inhibitor in Relapsed Ovarian Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Adults with recurrent high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (ECOG 0–2, up to 5 prior lines) receive oral NMS-03305293, a PARP1-selective, non-trapping PARP inhibitor, on Days 1–7 plus IV topotecan weekly in 28-day cycles. Excludes known BRCA/HRD, prior PARP outside approved use, prior topoisomerase (including ADC payloads), and significant cardiopulmonary/CNS issues; aims to enable combination with topotecan while minimizing PARP-related myelosuppression.

ClinicalTrials.gov ID: NCT06930755